Literature DB >> 32561967

The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.

Naoko Komura1, Seiji Mabuchi2,3, Kotaro Shimura1, Eriko Yokoi1, Katsumi Kozasa1, Hiromasa Kuroda1, Ryoko Takahashi1, Tomoyuki Sasano1, Mahiru Kawano1, Yuri Matsumoto1, Michiko Kodama1, Kae Hashimoto1, Kenjiro Sawada1, Tadashi Kimura1.   

Abstract

The aim of this study was to investigate the role of myeloid-derived suppressor cells (MDSC) in the induction of cancer stem-like cells (CSC) and programmed death ligand 1 (PD-L1) expression in ovarian cancer. CSC were defined as tumor cells expressing high levels of aldehyde dehydrogenase 1 (ALDH 1). We inoculated G-CSF-expressing or Mock-expressing ovarian cancer cells into mice, and the frequencies of MDSC and CSC in tumors of these models were compared by flow cytometry. To directly demonstrate the role of MDSC in the induction of CSC and the increase in PD-L1 expression, we performed in vitro co-culture. MDSC and CSC (ALDH-high cells) were more frequently observed in G-CSF-expressing cell-derived tumors than in Mock-expressing cell-derived tumors. Co-culture experiments revealed that MDSC increased the number of CSC via the production of PGE2. Moreover, PGE2 produced by MDSC increased tumor PD-L1 expression via the mammalian target of rapamycin (mTOR) pathway in ovarian cancer cells. In an in vitro experiment in which ovarian cancer cells were co-cultured with MDSC, higher expression of PD-L1 was observed in CSC than in non-CSC (ALDH-low cells). Furthermore, by immunofluorescence staining, we found that PD-L1 was co-expressed with ALDH1 in in vivo mouse models. In conclusion, PGE2 produced by MDSC increases the stem cell-like properties and tumor PD-L1 expression in epithelial ovarian cancer. Depleting MDSC may be therapeutically effective against ovarian cancer by reducing the number of CSC and tumor PD-L1 expression.

Entities:  

Keywords:  Cancer stem cell; Myeloid-derived suppressor cells; Ovarian cancer; Programmed death ligand 1

Mesh:

Substances:

Year:  2020        PMID: 32561967     DOI: 10.1007/s00262-020-02628-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  The regulatory role of long non- coding RNAs as a novel controller of immune response against cancer cells.

Authors:  Dina Mofed; Jihad I Omran; Salwa Sabet; Ahmed A Baiomy; Marwan Emara; Tamer Z Salem
Journal:  Mol Biol Rep       Date:  2022-10-07       Impact factor: 2.742

Review 2.  Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.

Authors:  Yunzhou Pu; Qing Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.

Authors:  Mengqi Zhang; Lulu Wang; Wan Liu; Tian Wang; Francesco De Sanctis; Lifang Zhu; Guizhong Zhang; Jian Cheng; Qin Cao; Jingying Zhou; Aldo Tagliabue; Vincenzo Bronte; Dehong Yan; Xianchun Wan; Guang Yu
Journal:  J Immunol Res       Date:  2022-06-22       Impact factor: 4.493

4.  Application Value of Combined Detection of DCE-MRI and Serum Tumor Markers HE4, Ki67, and HK10 in the Diagnosis of Ovarian Cancer.

Authors:  Quanzhi Wang; Hui Dong; Peng Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-06-14       Impact factor: 3.009

Review 5.  Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers.

Authors:  Seiji Mabuchi; Tomoyuki Sasano
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

6.  Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer.

Authors:  Kotaro Shimura; Seiji Mabuchi; Naoko Komura; Eriko Yokoi; Katsumi Kozasa; Tomoyuki Sasano; Mahiru Kawano; Yuri Matsumoto; Tadashi Watabe; Michiko Kodama; Kae Hashimoto; Kenjiro Sawada; Jun Hatazawa; Tadashi Kimura
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

Review 7.  Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.

Authors:  Seiji Mabuchi; Tomoyuki Sasano; Naoko Komura
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 8.  Cancer Stemness Meets Immunity: From Mechanism to Therapy.

Authors:  Peiwen Chen; Wen-Hao Hsu; Jincheng Han; Yan Xia; Ronald A DePinho
Journal:  Cell Rep       Date:  2021-01-05       Impact factor: 9.423

Review 9.  Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.

Authors:  Jia-Nan Cheng; Yi-Xiao Yuan; Bo Zhu; Qingzhu Jia
Journal:  Front Cell Dev Biol       Date:  2021-12-23

Review 10.  Myeloid cell heterogeneity in lung cancer: implication for immunotherapy.

Authors:  Sabina Sangaletti; Roberto Ferrara; Claudio Tripodo; Marina Chiara Garassino; Mario Paolo Colombo
Journal:  Cancer Immunol Immunother       Date:  2021-04-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.